Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
335 Leser
Artikel bewerten:
(1)

Analytical Wizards secures Series A funding from Sopris Capital

EDISON, New Jersey, Nov. 21, 2019 /PRNewswire/ -- Analytical Wizards, a New Jersey-based global healthcare analytics firm, has announced that it has secured Series A funding from Sopris Capital.

Founded in 2015 Analytical Wizards leverages the power of AI/ML, technology, and domain expertise to provide solutions that drive value and accelerate business for clients in the pharmaceutical and biotech industries. The company has doubled its revenues every year since its inception in 2015.

Analytical Wizards has two proprietary platforms: WIZ, an industry leading multi-channel optimization platform, and IZE, a powerful real world analytics platform that processes big data to enable analytics on demand and uses AI/ML to generate predictive, prescriptive insights and proactive triggers.

Analytical Wizards will employ the Series A investment to bolster product development efforts and accelerate the development of modules on the IZE platform that address analytical needs of Clinical Development and HEOR/Health Outcomes teams, in addition to those of Commercial Brand, Access, and Sales teams within pharma/biotech.

Commenting on the Series A funding, Andy Paul, founder and CEO of Sopris Capital, said, "In VC funding, we are constantly evaluating fresh ideas and business propositions, only a select few of which hold unique and compelling promise. Analytical Wizards has the potential to transform healthcare analytics, enabling significant efficiencies and delivering value across pharma and biotech organizations. We are excited about its trajectory and future growth."

"This is an important milestone in our exciting journey, one that marks the confidence of the investment community in the value of our offerings," said Ram Sharma, founder and CEO of Analytical Wizards. "The Sopris investment will provide a boost to our product development efforts and help us to meet the growing demands of our satisfied customers while also expanding our sales footprint and client base."

Jeff Kozloff, CEO of Trial Scope and an active entrepreneur and investor in the healthcare space has been an advisor to Analytical Wizards since inception and will join the Board of Directors, says " I'm thrilled to be working with the brilliant Analytical Wizards team. They have completely flipped the model on advanced analytics and their market-leading platforms put customers in control of a user-friendly AI engine. No more black box. No more lengthy timelines. The Analytical Wizards self-serve platform delivers what customers value most: control, transparency and speed."

"As active investors in technology-enabled healthcare services and SaaS companies, we recognize the compelling and differentiated value proposition of Analytical Wizards building tools that enhance efficiency and time-to-insights while providing scalability and repeatability to address key business problems across Commercial and Clinical organizations within pharma and biotech" said Abinav Sankar, Vice President of Sopris Capital who joins the Board of Directors for Analytical Wizards.

Following the Series A investment from Sopris, Jaya Subramaniam, a veteran Pharma-Biotech executive, will join the Board of Directors and the company as its Chief Strategy Officer.

About AnalyticalWizards:

AnalyticalWizards is a technology-enabled healthcare analytics company that leverages AI/ML, technology, healthcare domain expertise, and a consultative approach to drive efficiencies and deliver significant value to pharma and biotech businesses. Learn more at: www.analyticalwizards.com

About Sopris Capital

Based in New York, Sopris Capital is a venture capital firm that invests growth equity in technology-enabled business services and SaaS companies that are addressing enterprise-level pain points. Sopris seeks to be a value-added partner to fast-growing companies that have a validated business model, proven product/market fit, and a management team that can capitalize on the opportunity ahead. Learn more at: http://www.sopriscapital.com

CONTACT:

Ram Sharma, CEO, Analytical Wizards
Tel: 732-902-2032
Email: rsharma@analyticalwizards.com

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.